Multiple preclinical studies, including those in SCLC, breast, and colorectal cancers, demonstrate that SLFN11 loss can be overcome by targeting compensatory DDR pathways, particularly ATR, CHK1, and WEE1 (7, 56, 79, 80). The gene discussed is ATR; the disease is small cell lung carcinoma.